Pressmeddelanden

LIPIGON WELCOMES NEW INVESTORS AND PARTNERS

Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.

"We are very pleased to announce 3 new partners as stakeholders in Lipigon. With these new investors, we are getting the necessary long-term commitment that we need to grow and build a sustainable research based company. Fort Knox and Partnerinvest are experienced life science investors with the necessary financial means to support present and future capital needs. We are also bringing an excellent collaboration partner on board that compliment us very well. Antaros Medical is perfectly situated to support us when our programs reach clinical phases through their expertise in medical imaging and drug development." says co-founder and CEO Stefan K Nilsson. "There is a lot of excitement in the company. We have a very interesting year coming up and high expectations for the future."

The excitement is shared by the new investors;

"We feel proud to welcome Lipigon to the Fort Knox family, and look forward to be a part of Lipigon's journey" said Markus Olsson, CEO, Fort Knox.

Investment manager at Partnerinvest Mattias Eriksson fills in;

"Lipigon has leading knowledge within the area of metabolism and we see a great potential in the company. We are also very pleased to do this investment together with Fort Knox and Antaros." says Eriksson.

Antaros Medical's CEO, Johannes Hulthe, points out the synergy effects;

"We believe there are several synergy effects between the strong metabolic research focus in Lipigon and the experience Antaros Medical brings in terms of drug development as well as imaging methodologies to explore early efficacy signals in humans. We are proud to be part of the exciting journey that lies ahead", says Hulthe.

About Lipigon

Lipigon is a spin out from Umeå University in Sweden. The company was founded by leading scientists in the field of cellular lipid transport. Lipigon is currently focusing on the discovery and development of novel treatments for dyslipidemia and metabolic diseases. Learn more at: www.lipigon.se

For further information, please contact:
Stefan K. Nilsson, CEO, Lipigon Pharmaceuticals
e-mail: stefan@lipigon.se
Tel: +46 70 578 176

About Partnerinvest

Partnerinvest invests in potential growth companies in Norrbotten and Västerbotten. Partnerinvest started the business in 2010 by initiative of ALMI Invest AB and Norrlandsfonden. 50 % of the capital in the first fund (179 Mkr) came from the EU structural funds and the other 50% from the County Administrative Boards of Norrbotten and Västerbotten, Region Västerbotten and the owners ALMI Invest AB and Norrlandsfonden. Late in 2015 the second fund (160Mkr) became active. With the exception for the County Administrative Board of Västerbotten, the second fund has the same financers as the first fund. Learn more at: www.partnerinvestnorr.se.

For further information, please contact:
Mattias Eriksson, Investment Manager at Partnerinvest Övre Norrland AB,
mattias@partnerinvestnorr.se

About Fort Knox

Fort Knox is not only a company with a focus on asset management. We are an entrepreneurial company that invests in companies with ideas that can grow. Fort Knox is a company that believes in Umeå.

About Antaros Medical

Antaros Medical is an R&D company within the Life Science area. The company is pioneering new frontiers in innovative PET and MR imaging methods, leading to improved, evidence-based decision making in clinical drug development. The company is specialized in cardio-metabolic diseases and oncology. Antaros Medical has a global network of customer including both big and small drug developing companies. Learn more at: www.antarosmedical.com

For further information, please contact:
Johannes Hulthe, CEO,
johannes.hulthe@antarosmedical.com

2017-12-09

Lipigons VD Dr. Stefan K Nilsson väljs in i The European Lipoprotein Club (ELC), det äldsta och mest aktiva europeiska nätverket inom lipidfältet. ELC etablerades 1977 för att främja samarbete och utbyte av idéer inom grundforskning och klinisk forskning på lipoproteiner (blodfettskomplex).

2017-10-10

Lipigon Pharmaceuticals ("Lipigon") tillkännagav idag att bolaget har tecknat avtal avseende validering av målprotein för läkemedelsutveckling med Secarna Pharmaceuticals ("Secarna") som är specialiserat på RNA-behandlingar genom s.k. antisens-teknologi. Målet är att tillsammans utveckla ett läkemedel som är best-in-class för behandling av allvarliga former av dyslipidemi (allmänna blodfettsrubbningar) och närliggande sjukdomar.

2017-10-10

Lipigon Pharmaceuticals ("Lipigon") announced today that it has entered into a Target Validation Research Agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals ("Secarna"). The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases.

2016-12-26

Starting December 2016 Lipigon joins the AZ BioVentureHub located at AstraZeneca's site in Mölndal, Sweden. The contract stretches over 1 year giving Lipigon an office and full access to the whole facility, including infrastructure and capabilities.

2016-12-01

Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.

2016-03-13

Lipigon Pharmaceuticals today announced that it has entered into a research collaboration with AstraZeneca to conduct joint research to identify drug candidates that promote the stabilization of Lipoprotein Lipase (LPL) and may have utility in the treatment of lipid disorders and cardiovascular disease.

2014-11-17

UMEÅ, November 18th. Lipigon Pharmaceuticals and AstraZeneca enter research collaboration to develop a high throughput assay for the identification of molecules that modulate lipoprotein lipase activity

<<
1
...
9
10
11

Nyheter

11 juli, 2022, Pressmeddelande

Sista dag för handel med BTA i Lipigon

Företrädesemissionen i Lipigon Pharmaceuticals AB (publ) ("Bolaget" eller "Lipigon") är nu registrer...

21 juni, 2022, Pressmeddelande

Lipigon tillförs 22,6 MSEK i emissionslikvid

Lipigon Pharmaceuticals AB (publ) ("Bolaget" eller "Lipigon") meddelar härmed utfallet i den företrä...

13 juni, 2022, Pressmeddelande

Lipigons vd om emissionen och den nystartade fas I-studien

Lipigon beslutade i maj om en nyemission av aktier om drygt 21 MSEK med företrädesrätt för Lipigons ...